A biotech startup spun out of the University of Washington and led by veterans of Seattle-area biotech giant Seagen has raised $4.4 million, part of an ongoing seed round.
The leaders of the startup, Abacus Bioscience, say they’ve landed on a new, potentially powerful approach to create vaccines to treat people with cancer.
Anti-tumor vaccines have been tested for decades and some are approved, but they have shown limited effectiveness.
